CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Ashleigh M FordhamJinhan XieAndrew J GiffordCarol WadhamLisa T MorganEmily V A MouldMitali FadiaLei ZhaiHassina MassudiZara S AliGlenn M MarshallRobyn E LukeisJamie I FletcherKaren L MacKenzieToby N TrahairPublished in: British journal of cancer (2020)
CD30 is a therapeutic target in eIMS. BV efficacy is limited by the rapid emergence of resistance. Prolonged survival with combination ALK and CD30-targeted-therapy in the diagnosis model provides the rationale to trial this combination in eIMS patients at diagnosis. This combination could also be considered for other CD30-positive, ALK-rearranged malignancies.
Keyphrases
- combination therapy
- advanced non small cell lung cancer
- end stage renal disease
- clinical trial
- nk cells
- chronic kidney disease
- newly diagnosed
- oxidative stress
- ejection fraction
- randomized controlled trial
- study protocol
- prognostic factors
- peritoneal dialysis
- inflammatory response
- lipopolysaccharide induced
- lps induced